Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by robinee3on Nov 05, 2011 3:46pm
396 Views
Post# 19212699

Th sera-t-il en vit dans 1 an ?

Th sera-t-il en vit dans 1 an ?
 Pour la fin du 4 ième trimestre, fin novembre, il restera dans les coffres environ un maigre 30 millions. En dépensant environ 7 à 10 millions par trimestre, TH pourra à peine survivre pour 4 autres trimestres. Donc, on s'en va nécessairement vers une nouvelle émission d'action, à moins qu'il y ait une offre d'achat hostile à rabais par l'un des partenaires commerciale, au cours de la prochaine année. J'aimerais bien savoir ce qu'en pense SPCEO1.
 
Tous les commentaires sont le bienvenus et vont nous aider à la compréhension de cette piteuse gestion.

 Robinee 
Bullboard Posts